Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SANGUINE CORP. (SGNC) -- Ignore unavailable to you. Want to Upgrade?

To: Lazarus Long who wrote (3055)	7/12/1998 7:23:00 PM
From: Prospector	Read Replies (2) \| Respond to of 5402

Market Place One half of U. S. heart attack victims die before reaching the emergency room. This represents approximately 750,000 victims of the 1,500,000 heart attack cases per year. The Marketplace for blood substitute products number over 150 specific procedures. For the purpose of the short-term and long-term targets, the following application will be the primary focus of the company: Transfusion: Transfusions will be the largest potential long-range market for PHER-02. there are 60,000,000 transfusions annually in the world. If there were a plentiful supply of non-infected transfusion material, the actual number of transfusions needed worldwide would double to 120,000,000 per year, according to U.S. Hematologists and the World Health Organization,, Geneva. followed by heart attack, Stroke, head and neck cancer, and Cardioplegia which I have already posted.. Prospector